Overview

Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
0
Participant gender:
All
Summary
This study seeks to prospectively demonstrate that Nasonex is better than placebo in relieving nasal congestion in patients with seasonal allergic rhinitis.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Mometasone Furoate
Criteria
Inclusion Criteria:

- A subject must be 12 years of age or older, of either sex, and of any race.

- A subject must have at least a 2-year history of SAR which exacerbates during the
study season.

- A subject must have a positive skin prick test response to an appropriate seasonal
allergen at Visit 1.

- A subject must be clinically symptomatic at the Screening and Baseline Visits.

Exclusion Criteria:

- A subject with a history of severe local reaction(s) or anaphylaxis to skin testing.

- A subject who has had an upper respiratory tract or sinus infection that required
antibiotic therapy without at least a 14-day washout prior to the Screening Visit, or
who has had a viral upper respiratory infection within 7 days prior to the Screening
Visit.

- A subject who has used any drug in an investigational protocol in the 30 days prior to
the Screening Visit.

- A subject who is participating in any other clinical study.

- A subject who is part of the staff personnel directly involved with this study.

- A subject who is a family member (parent, spouse, or sibling) of the investigational
study staff.

- A female subject who is breast-feeding, pregnant, or intends to become pregnant.

- A subject previously randomized into this study.

- A subject who has a family member (parent, spouse, or sibling) currently enrolled in
this study.